Saturday , September 26 2020
Breaking News
Home / World News / Vaccine nationalism: US says it won’t join global effort for COVID-19 inoculation

Vaccine nationalism: US says it won’t join global effort for COVID-19 inoculation

The WHO says even governments making deals with individual vaccine makers would benefit from joining COVAX because it would provide backup vaccines in case the ones being made through bilateral deals with manufacturers aren’t successful.

“The United States will continue to engage our international partners to ensure we defeat this virus, but we will not be constrained by multilateral organisations influenced by the corrupt World Health Organisation and China,” said White House spokesman Judd Deere.

Going it alone on vaccines: US President Donald Trump.

Going it alone on vaccines: US President Donald Trump.Credit:AP

“This president will spare no expense to ensure that any new vaccine maintains our own Food and Drug Administration’s gold standard for safety and efficacy, is thoroughly tested and saves lives.”

Representative Ami Bera said the administration’s decision was shortsighted and will hamper the battle to end the pandemic.

“Joining COVAX is a simple measure to guarantee US access to a vaccine — no matter who develops it first,” tweeted Bera, a medical doctor. “This go-it-alone approach leaves America at risk of not getting a vaccine.”

Loading

The administration’s decision, paired with the U.S. withdrawal from the WHO, means the U.S. is abdicating America’s global leadership in fighting pandemics, according to Tom Hart, North America director at The ONE Campaign, an advocacy organisation co-founded by Bono of the rock band U2.

“Not only does this move put the lives of millions around the world at risk, it could completely isolate Americans from an effective vaccine against COVID-19,” Hart said.

A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle — looking for the needed proof that they really work.

AstraZeneca announced on Monday its vaccine candidate has entered the final testing stage in the US. The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.

Two other vaccine candidates began final testing this summer in tens of thousands of people in the US One was created by the National Institutes of Health and manufactured by Moderna, and the other developed by Pfizer Inc. and Germany’s BioNTech.

AP

Most Viewed in World

Loading

About admin

Check Also

Stabbing attack near former offices of Charlie Hebdo magazine in Paris

At least two people were wounded in the knife attack on Friday near the former …